Clinical Trial Update: A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

This is a Phase 1 dose-finding and exploratory study evaluating RO5323441 in combination with sorafenib for hepatocellular carcinoma that has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• RO5323441 (RO5323441)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Carcinoma, Hepatocellular | Phase 1 | Status: COMPLETED